Linda Yaccarino, the former CEO of Elon Musk’s X, has been appointed as the new chief executive officer of eMed, a health tech startup focused on developing a platform for patients using GLP-1 medications.
Why it matters: Yaccarino’s move to eMed marks a significant career shift and is expected to draw more attention to the startup, given her visibility and reputation in the tech world.
The details:
- eMed initially gained recognition for its tech platform designed to assist users with administering at-home COVID-19 rapid antigen tests.
- The company is now concentrating on GLP-1s, a class of drugs such as Ozempic, used for weight management and treating type 2 diabetes.
- Although Yaccarino does not possess prior experience in health tech, eMed emphasized her “undeniable ability to negotiate new partnerships” as a key factor in her appointment.
Yaccarino played a significant role in addressing X’s ad revenue challenges alongside Elon Musk during her two-year tenure at the social media platform.
What they’re saying:
- “To be a leader in today’s healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow but to also be brave enough to step forward and redefine an entire industry,” Yaccarino stated in a press release.
- “We are well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms,” she added.
What’s next: As eMed’s new CEO, Yaccarino is expected to leverage her experience and reputation to expand the company’s partnerships and advance its mission of making chronic care more accessible through a digital-first approach.
